UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CD70: An emerging target in cancer immunotherapy

Pharmacology & therapeutics (Oxford), 2015-11, Vol.155, p.1-10

2015

Volltextzugriff (PDF)

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

Annals of oncology, 2011-05, Vol.22 (5), p.1078-1087

2011

Volltextzugriff (PDF)

Serial comprehensive geriatric assessment in elderly head and neck cancer patients undergoing curative radiotherapy identifies evolution of multidimensional health problems and is indicative of quality of life

European journal of cancer care, 2014-05, Vol.23 (3), p.401-412

2014

Volltextzugriff (PDF)

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

Annals of oncology, 2010-10, Vol.21 (10), p.1967-1973

2010

Volltextzugriff (PDF)

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration

Annals of oncology, 2024-09

2024

Volltextzugriff (PDF)

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

Annals of oncology, 2012-10, Vol.23 (10), p.2663-2670

2012

Volltextzugriff (PDF)

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Investigational new drugs, 2014-12, Vol.32 (6), p.1278-1284

2014

Volltextzugriff (PDF)

A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?

Annals of hematology, 2018-03, Vol.97 (3), p.545-546

2018

Volltextzugriff (PDF)

PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii20-viii20

2018

Volltextzugriff (PDF)

A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors

Annals of oncology, 2013-05, Vol.24 (5), p.1392-1400

2013

Volltextzugriff (PDF)

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

ESMO open, 2022-10, Vol.7 (5), p.100562-100562, Article 100562

2022

Volltextzugriff (PDF)

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial

ESMO open, 2023-08, Vol.8 (4), p.101584-101584, Article 101584

2023

Volltextzugriff (PDF)

NEPHROTOXICITY OF ANTICANCER DRUGS - AN UNDERESTIMATED PROBLEM?

Acta clinica belgica (English ed. Online), 2011-09, Vol.66 (5), p.337-345

2011

Volltextzugriff (PDF)

A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study

ESMO open, 2021-10, Vol.6 (5), p.100242-100242, Article 100242

2021

Volltextzugriff (PDF)

Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions

Journal of clinical pharmacy and therapeutics, 2014-06, Vol.39 (3), p.259-265

2014

Volltextzugriff (PDF)

PO-087: Adaptive 18F-FDG-PET-guided reirradiation for recurrent and second primary head and neck cancer

Radiotherapy and oncology, 2017-03, Vol.122, p.41-42

2017

Volltextzugriff (PDF)

108 CD70 (TNFSF7), a receptor involved in acute immune modulation of viral infection, is frequently overexpressed in solid and hematological malignancies

European journal of cancer (1990), 2014-11, Vol.50, p.39-39

2014

Volltextzugriff (PDF)

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future

ESMO open, 2022-12, Vol.7 (6), p.100610-100610, Article 100610

2022

Volltextzugriff (PDF)

2880 Immunohistochemical analysis of CD70 expression in 95 cases of squamous cell carcinoma of the head and neck: Correlation with clinicopathological variables and identification of a novel therapeutic target

European journal of cancer (1990), 2015-09, Vol.51, p.S583-S584

2015

Volltextzugriff (PDF)

Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis

European journal of cancer (1990), 2021-07, Vol.152, p.165-182

2021

Volltextzugriff (PDF)

Necrotizing myopathy as a paraneoplastic syndrome associated with renal cell carcinoma

Acta clinica belgica (English ed. Online), 2015-02, Vol.70 (1), p.61-64

2015

Volltextzugriff (PDF)

PARP-remmers bij gemetastaseerde prostaatkanker: een systematische review

Tijdschrift voor geneeskunde, 2022-02

2022

Volltextzugriff (PDF)

616 Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma

European journal of cancer (1990), 2012-11, Vol.48, p.190-190

2012

Volltextzugriff (PDF)

604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial

European journal of cancer (1990), 2012-11, Vol.48, p.185-186

2012

Volltextzugriff (PDF)

1 – 25 von 362

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(339)
Mit Volltextzugriff
(283)

Publikationsform

Artikel
(351)
Berichte
(6)
Webseiten
(3)
Reviews
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

CD70: An emerging target in cancer immunotherapy

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

Serial comprehensive geriatric assessment in elderly head and neck cancer patients undergoing curative radiotherapy identifies evolution of multidimensional health problems and is indicative of quality of life

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?

PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors

A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial

NEPHROTOXICITY OF ANTICANCER DRUGS - AN UNDERESTIMATED PROBLEM?

A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study

Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions

PO-087: Adaptive 18F-FDG-PET-guided reirradiation for recurrent and second primary head and neck cancer

108 CD70 (TNFSF7), a receptor involved in acute immune modulation of viral infection, is frequently overexpressed in solid and hematological malignancies

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future

2880 Immunohistochemical analysis of CD70 expression in 95 cases of squamous cell carcinoma of the head and neck: Correlation with clinicopathological variables and identification of a novel therapeutic target

Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis

PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment

Necrotizing myopathy as a paraneoplastic syndrome associated with renal cell carcinoma

PARP-remmers bij gemetastaseerde prostaatkanker: een systematische review

616 Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma

604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial

Suchergebnisse filtern